Welcome to industryreportstore.com

Need help? +44(0)20 7936 6830

Pharmaceuticals market research, reports and industry analysis

mail

Contact us for professional industry advice

Email us or call

+44(0)20 7936 6830
mail

for FREE research alerts
to your inbox

92 Item(s)

Page 1 of 10

  1. PharmaPoint: Psoriatic Arthritis - Global Drug Forecast and Market Analysis to 2025

    By: GlobalData
    , Published: Dec-2016
    , Product code: GDHC140PIDR
    Psoriatic arthritis (PsA) is a chronic immune-mediated arthritis typically affecting the large joints, especially those of the lower extremities and distal joints of the fingers and toes as well as the back and sacroiliac joints of the pelvis. In approximately 80% of PsA patients, skin lesions of psoriasis (PsO), an immune-mediated skin disease, manifest prior to the development of PsA, typically by five to 10 years. PsA most commonly develops between the ages of 30 and 50 and affects men and women equally. Although, early diagnosis and intervention are key in preventing irreversible joint damage, many PsA patients are undiagnosed and go untreated for months or years.
    $10,995.00

  2. PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025

    By: GlobalData
    , Published: Oct-2016
    , Product code: GDHC126PIDR
    Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. It is characterized by single or recurrent major depressive episodes (MDEs), where patients can typically experience periods of depressed mood, loss of energy, abnormal cognition, anxiety and suicidal ideation. Similar to other neuropsychiatric disorders, MDD has a multifaceted and varied etiology, and remains poorly understood. The MDD market is crowded and competitive, with more than 30 products available for the treatment of patients, the majority of which are now available as inexpensive generics. The MDD market is therefore in a dynamic phase where patent expiries for historically top-selling products such as Eli Lilly’s Cymbalta and Otsuka/BMS’ Abilify have occurred, and recent launches of Lundbeck/Takeda’s Trintellix and Otsuka/Lundbeck’s Rexulti will be a significant driver of growth in the 7MM. Growth in the MDD market is also expected to be driven by the potential introduction of six promising late-stage pipeline products into the market during the forecast period, all of which are directed towards treatment-resistant patients, a significant unmet need.
    $10,995.00

  3. PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

    By: GlobalData
    , Published: Sep-2016
    , Product code: GDHC125PIDR
    Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels of inattention, impulsivity, and hyperactivity, either alone or in combination that have a significant social impact through disruptions at school, work, home, and in relationships. The majority of children with the disorder will continue to experience symptoms into adolescence. 30-50% of children diagnosed with ADHD continue to have problems into adulthood resulting in 2-¬5% of adults having ADHD.
    $10,995.00

  4. PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

    By: GlobalData
    , Published: Aug-2016
    , Product code: GDHC131PIDR
    Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality in the world. The term acute coronary syndrome (ACS) applies to a spectrum of acute CVD states that are precipitated by coronary artery occlusion (stenosis) that results in ischemia (a reduction or loss of blood flow to tissue) and the necrosis of myocardial tissue .In the most modern use of the term, ACS strictly refers to a range of ischemic cardiovascular events that includes unstable angina (UA), myocardial infarction (MI) and/or death due to myocardial ischemia. In general, these ACS events can be viewed as the culmination of coronary artery disease (CAD), the asymptomatic build-up of atherosclerotic plaque on the walls of the coronary arteries. The triggering of an ACS event stemming from UA or MI initiates the acute phase treatment setting where therapeutic interventions are utilized to reverse and prevent the physiochemical processes that lead to coronary stenosis. Whereas, the chronic phase treatment setting involves secondary preventative measures that are used to avoid recurrent ACS events from occurring.
    $10,995.00

  5. PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025

    By: GlobalData
    , Published: Aug-2016
    , Product code: GDHC132PIDR
    Venous thromboembolism (VTE) is a disease that includes a myriad of life-threatening disorders ranging from pulmonary embolism (PE) to deep vein thrombosis (DVT. The condition is relatively prevalent and is associated with long-term mortality and morbidity. VTE occurs when a thrombus (blood clot) forms in an individual’s deep vein, owing to either changes in the components of their blood, damage to the endothelium in the vasculature, and/or changes in the flow of blood). When a thrombus materializes in the veins of the lower extremities, it can embolize, potentially occluding blood vessels in the lungs. Consequently, the vast majority of patients presenting with symptomatic pulmonary embolism also suffer from deep vein thrombosis, and many individuals diagnosed with deep vein thrombosis display pulmonary embolism that is asymptomatic. VTE can arise in both non-hospitalized and hospitalized individuals, repeatedly returns, and can cause chronic complications, such as post-thrombotic syndrome (PTS) or chronic thromboembolic pulmonary hypertension (CTEPH).
    $10,995.00

  6. PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025

    By: GlobalData
    , Published: Aug-2016
    , Product code: GDHC133PIDR
    Atrial fibrillation (AF) is the most common cardiac arrhythmia and is a heart condition that causes an irregular and often abnormally fast heart rate. Various therapeutic options are available to treat patients with AF, and most patients will receive some form of antithrombotic therapy, a heart rate control agent, and potentially an antiarrhythmic drug for rhythm control.
    $10,995.00

  7. OpportunityAnalyzer: Osteoarthritis - Opportunity Analysis and Forecasts to 2024

    By: GlobalData
    , Published: Jun-2016
    , Product code: GDHC043POA
    Osteoarthritis (OA) is a slowly progressive joint disease that is typically seen in middle-aged to elderly people. The disease is caused by the breakdown of the joint cartilage due to mechanical stress or biochemical alterations, which causes the bone underneath to fail. OA can occur together with other types of arthritis, such as gout or rheumatoid arthritis (RA). OA tends to affect commonly used joints such as the hands and spine as well as the weight-bearing joints such as the hips and knees. The causes of OA are not fully understood. However, genetic factors, and damage to the joints, either through repeated excessive loading and stress of a joint over time (for example, the knee joint in an obese person) or by injury (such as a break or dislocation of a finger joint) increases the risk of developing OA. There is no single test to diagnose OA. Several methods are used to diagnose OA and to rule out other problems: medical history, physical exam, X-rays, blood tests, or joint fluid analysis. The structural changes that occur with old age may not be accompanied by symptoms, which makes the estimation of the prevalence of OA difficult.
    $10,995.00

  8. OpportunityAnalyzer: Idiopathic Pulmonary Fibrosis - Opportunity Analysis and Forecast to 2025

    By: GlobalData
    , Published: Jun-2016
    , Product code: GDHC059POA
    The IPF therapeutic market is currently dominated by the only two drugs that have gained marketing approval for IPF - Roche’s Esbriet and Boehringer Ingelheim’s Ofev. Esbriet was the first drug to gain approval for IPF in 2011 when it was approved for use in Europe, a full four years before rival Ofev. However, both gained approval into the largest IPF market of the US on the same day in October 2014. The top-selling drug in IPF in value terms is Roche’s Esbriet, which GlobalData estimates generated approximately $572m in 2015 from the seven major markets. There is high R&D activity for the development of new therapies for IPF and eight promising therapies can potentially enter the market from 2015 to 2025. Numerous novel targets are being studied in the IPF pipeline, with major pharmaceutical players Roche, Sanofi, Bristol-Myers Squibb, and Biogen all active in the development process. Other promising pipeline candidates include FibroGen’s CTGF inhibitor, Promedior’s PTX2 protein, Afferent’s P2X3 receptor antagonist, and MediciNova’s 5-LO/LT pathway inhibitor. The continued uptake of Esbriet and Ofev, combined with the introduction of new novel drugs will shape the future competitive landscape and drive growth in the IPF market.
    $10,995.00

  9. PharmaPoint: Type 2 Diabetes - Global Drug Forecast and Market Analysis to 2025

    By: GlobalData
    , Published: Jun-2016
    , Product code: GDHC128PIDR
    The type 2 diabetes market is mature and crowded with inexpensive generics. Despite being marked by a late-stage pipeline filled with me-too drugs, this market will undergo substantial growth between 2015 and 2025, almost doubling over this period. The main drivers of growth will be the dramatic increase in disease prevalence and physicians’ efforts to delay disease progression and reduce the costly burden of diabetic complications through the use of combination therapies and novel branded drugs. We anticipate that the type 2 diabetes market will experience a shift in the classes of drugs that are preferred by physicians. Rapid uptake of drugs from the glucagon-like peptide-1 receptor agonist (GLP-1RA) class and sodium-glucose co-transporter-2 inhibitor (SGLT-2I) class will occur; while dipeptidyl peptidase-4 inhibitors (DPP-4Is) will continue to grow, but at a much slower rate than previous years. GLP-1RAs and SGLT-2Is will experience the fastest growth of all classes at a CAGR of 12.2% and 13.0% respectively.
    $10,995.00

  10. PharmaPoint: Meningococcal Vaccines - Global Drug Forecast and Market Analysis to 2025

    By: GlobalData
    , Published: May-2016
    , Product code: GDHC115PIDR
    Neisseria meningitidis is a Gram-negative, encapsulated diplococcal bacterium and is the causative agent for invasive meningococcal disease. Although relatively rare around the globe, invasive meningococcal disease is widely feared because of its high mortality rate even in otherwise healthy individuals. The onset of invasive meningococcal disease typically begins within three to seven days of infection, but can occur as early as one day after infection. If left untreated, meningococcal disease progresses rapidly. Even with appropriate treatment, up to 10% of all cases still result in death within 24 to 48 hours of symptom onset. This rapid onset and progression of the disease emphasizes the need for a prophylactic approach by vaccination.
    $10,995.00

92 Item(s)

Page 1 of 10